248 related articles for article (PubMed ID: 34417905)
21. Willingness to pay for QALY: perspectives and contexts in Japan.
Igarashi A; Goto R; Yoneyama-Hirozane M
J Med Econ; 2019 Oct; 22(10):1041-1046. PubMed ID: 31262236
[No Abstract] [Full Text] [Related]
22. Willingness to Pay for a Quality-Adjusted Life Year among Gastrointestinal Cancer Patients at a Tertiary Hospital of Vietnam, 2022.
Tran BT; Tran TT; La NQ; Nguyen TTP; Nguyen MH; Huynh TMC; Vu HP
Asian Pac J Cancer Prev; 2024 May; 25(5):1725-1735. PubMed ID: 38809645
[TBL] [Abstract][Full Text] [Related]
23. The value of a QALY: individual willingness to pay for health gains under risk.
Bobinac A; van Exel J; Rutten FF; Brouwer WB
Pharmacoeconomics; 2014 Jan; 32(1):75-86. PubMed ID: 24293198
[TBL] [Abstract][Full Text] [Related]
24. Eliciting the Monetary Value of a Quality-Adjusted Life Year in a Greek Outpatient Department in Times of Economic Austerity.
Mavrodi A; Aletras V; Spanou A; Niakas D
Pharmacoecon Open; 2017 Dec; 1(4):291-300. PubMed ID: 29441505
[TBL] [Abstract][Full Text] [Related]
25. WTP for a QALY and health states: More money for severer health states?
Shiroiwa T; Igarashi A; Fukuda T; Ikeda S
Cost Eff Resour Alloc; 2013; 11():22. PubMed ID: 24128004
[TBL] [Abstract][Full Text] [Related]
26. The value of a QALY towards the end of life and its determinants: Experimental evidence.
Fischer B; Telser H; Zweifel P; von Wyl V; Beck K; Weber A
Soc Sci Med; 2023 Jun; 326():115909. PubMed ID: 37121067
[TBL] [Abstract][Full Text] [Related]
27. Willingness to pay for a QALY.
Gyrd-Hansen D
Health Econ; 2003 Dec; 12(12):1049-60. PubMed ID: 14673813
[TBL] [Abstract][Full Text] [Related]
28. Willingness to pay for a QALY: theoretical and methodological issues.
Gyrd-Hansen D
Pharmacoeconomics; 2005; 23(5):423-32. PubMed ID: 15896094
[TBL] [Abstract][Full Text] [Related]
29. Estimating a WTP-based value of a QALY: the 'chained' approach.
Robinson A; Gyrd-Hansen D; Bacon P; Baker R; Pennington M; Donaldson C;
Soc Sci Med; 2013 Sep; 92():92-104. PubMed ID: 23849283
[TBL] [Abstract][Full Text] [Related]
30. Sample restrictions and the elicitation of a constant willingness to pay per quality adjusted life year.
Nielsen JS; Gyrd-Hansen D; Kjaer T
Health Econ; 2021 May; 30(5):923-931. PubMed ID: 33569834
[TBL] [Abstract][Full Text] [Related]
31. Willingness-to-Pay for One Quality-Adjusted Life-Year: A Population-Based Study from Iran.
Lankarani KB; Ghahramani S; Moradi N; Shahraki HR; Lotfi F; Honarvar B
Appl Health Econ Health Policy; 2018 Dec; 16(6):837-846. PubMed ID: 30123949
[TBL] [Abstract][Full Text] [Related]
32. Monetary value of health-a practical decision-making framework combining equity considerations and WTP.
Ribarić E; Velić I; Bobinac A
Eur J Health Econ; 2024 May; ():. PubMed ID: 38769211
[TBL] [Abstract][Full Text] [Related]
33. The Willingness to Pay for a Quality Adjusted Life Year: A Review of the Empirical Literature.
Ryen L; Svensson M
Health Econ; 2015 Oct; 24(10):1289-1301. PubMed ID: 25070495
[TBL] [Abstract][Full Text] [Related]
34. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
Shepherd J; Jones J; Takeda A; Davidson P; Price A
Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
[TBL] [Abstract][Full Text] [Related]
35. Exploring the willingness to pay for a quality-adjusted life-year in the state of Penang, Malaysia.
Shafie AA; Lim YW; Chua GN; Hassali MA
Clinicoecon Outcomes Res; 2014; 6():473-81. PubMed ID: 25364267
[TBL] [Abstract][Full Text] [Related]
36. QALY-type preference and willingness-to-pay among end-of-life patients with cancer treatments: a pilot study using discrete choice experiment.
Yin Y; Peng Q; Ma L; Dong Y; Sun Y; Xu S; Ding N; Liu X; Zhao M; Tang Y; Mei Z; Shao H; Yan D; Tang W
Qual Life Res; 2024 Mar; 33(3):753-765. PubMed ID: 38079024
[TBL] [Abstract][Full Text] [Related]
37. Preferences for improvements in attributes associated with basal insulin: a time trade-off and willingness-to-pay survey of a diabetic and non-diabetic population in Sweden.
Olofsson S; Norrlid H; Persson U
J Med Econ; 2016 Oct; 19(10):945-58. PubMed ID: 27149402
[TBL] [Abstract][Full Text] [Related]
38. Estimating the cost-effectiveness threshold of advanced non-small cell lung cancer in China using mean opportunity cost and contingent valuation method.
Peng Q; Yin Y; Liang M; Zhao M; Shao T; Tang Y; Mei Z; Li H; Tang W
Cost Eff Resour Alloc; 2023 Nov; 21(1):80. PubMed ID: 37915053
[TBL] [Abstract][Full Text] [Related]
39. Willingness to pay per quality-adjusted life year in a study of knee osteoarthritis.
Byrne MM; O'malley K; Suarez-Almazor ME
Med Decis Making; 2005; 25(6):655-66. PubMed ID: 16282216
[TBL] [Abstract][Full Text] [Related]
40. Value of willingness to pay for a QALY gained in Iran; a modified chained-approach.
Jahanbin SF; Yusefzadeh H; Nabilou B; Alinia C
BMC Health Serv Res; 2021 Dec; 21(1):1339. PubMed ID: 34906099
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
